CurrentcignaPolicy IP0261

Multiple Sclerosis (Oral - Other) Cladribine

Cigna coverage policy for oral cladribine (Mavenclad/generic) for treatment of relapsing forms of multiple sclerosis in adults, specifying prior authorization requirements, initial and continuation approval criteria, exclusions, prescribing specialist requirement, and coding/billing guidance context.

Policy Summary

Payercigna

PolicyMultiple Sclerosis (Oral - Other) Cladribine

Policy CodePolicy IP0261

Change TypeCriteria additions and revisions (material)

Effective DateMar 1, 2026

Next Review Date

Key ActionPrior authorization must be obtained for cladribine; approvals are issued for the durations specified (initial and reauthorization: 1 year).

SourceLink

POLICY UPDATE CHANGES

Added new criterion allowing inadequate efficacy or intolerance to two disease-modifying agents as an alternative pathway for initial therapy.

Added specific list of high-efficacy agents (Kesimpta, natalizumab IV product, Briumvi, Lemtrada, Ocrevus, Ocrevus Zunovo) that qualify for the one-alternative exception.

Updated reauthorization requirements by adding specific examples of beneficial clinical response and added alternative reauthorization criterion for stabilization/improvement in symptoms.

Added a specialist prescribing requirement.

Removed preferred product requirements for Employer and IFP.

Added a definition for documentation (selected revision dated 12/1/2024).

Policy name changed to add 'Oral - Other' and generic Mavenclad was added with related criterion changes.

1Initial approval duration (years)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

1Reauthorization duration (years)

3Example objective measures listed

3Not-covered major categories

Coverage Summary

Cladribine (Mavenclad) for Multiple Sclerosis — Status: CURRENT. Payer: Cigna Companies. Policy number: IP0261. Effective date: 2026-03-01.

Coverage stance: Covered with criteria. Prior authorization is required for benefit coverage and approvals are issued for 1 year for both initial therapy and reauthorization (durations noted in the FDA-Approved Indication sections).

Prescribing requirement: medication must be prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis. (Specialist involvement is required due to evaluation, diagnosis, and monitoring needs.)

Quick Reference — Approval Durations & Key Stats

Approval duration - Initial therapy1 year

Approval duration - Reauthorization1 year

Example objective measures listed for reauthorization (count)3

Major not-covered categories (count)3

Prescribing requirementMust be prescribed by or in consultation with a neurologist or MS specialist

Medical Necessity Criteria

FDA-Approved Indication - Multiple Sclerosis

Approve for the duration noted below if the patient meets ONE of the following (A or B):

ANY of the following

A) Initial Therapy
- Patient has a relapsing form of multiple sclerosis
  Examples include relapsing remitting disease and active secondary progressive disease
- ONE of
  - a) Two prior DMTs: According to the prescriber, the patient has experienced inadequate efficacy or significant intolerance to two disease-modifying agents used for multiple sclerosis
    See Appendix for examples

Provider Actions & Administrative Requirements

Prior Authorization

Prior authorization required

Prior authorization must be obtained for cladribine; approvals are issued for the durations specified (initial and reauthorization: 1 year).

Documentation Required

Prescriber specialty documentation

Medication must be prescribed by or in consultation with a neurologist or physician specializing in MS; documentation should reflect specialist involvement.

Coding

drug NDC / productNDC

No codes listed

Background and Evidence

Background: Cladribine is a purine antimetabolite indicated for relapsing forms of multiple sclerosis in adults (examples include relapsing-remitting disease and active secondary progressive disease). Use is generally reserved for patients with an inadequate response to, or who are unable to tolerate, alternative disease-modifying therapies.

Safety and warnings: Cladribine carries a Boxed Warning for malignancy and teratogenicity. Additional contraindications and precautions include current malignancy, pregnancy, lack of effective contraception for patients of reproductive potential (during dosing and for 6 months after last dose per warnings), HIV, active chronic infection (e.g., hepatitis or tuberculosis), hypersensitivity to cladribine, and breastfeeding restrictions; warnings include lymphopenia, infections, hematologic toxicity, graft-versus-host disease with blood transfusion, and liver injury.

Use considerations: The policy reserves cladribine for patients after inadequate efficacy or significant intolerance to alternative DMTs (policy updated to allow failure of two disease-modifying agents as one pathway, or inadequate response/intolerance to one specified high-efficacy agent). Prescribing must be by or in consultation with a neurologist or MS specialist.

Definitions & Key Terms

Evidence & References

Revision History

08/15/2024change

Added new initial-therapy criterion allowing inadequate efficacy or significant intolerance to two disease-modifying agents as an alternative pathway for starting cladribine (material).

08/15/2024change

Added specific list of high-efficacy agents that qualify for the one-alternative exception for initial therapy, explicitly including Kesimpta, natalizumab IV product (Tysabri, biosimilar), Briumvi, Lemtrada, Ocrevus, and Ocrevus Zunovo (material).

08/15/2024change

Updated reauthorization requirements to add specific examples of beneficial clinical response (MRI, EDSS, NEDA, FSIQ-RMS, six-minute walk/12-Item MS Walking Scale, MSFC, attenuation of brain volume loss) and added an alternative reauthorization criterion for stabilization/slowed progression or improvement in at least one symptom (motor, fatigue, vision, bowel/bladder, spasticity, walking/gait, pain/numbness/tingling) (material).

Policy Summary

Payercigna

PolicyMultiple Sclerosis (Oral - Other) Cladribine

Policy CodePolicy IP0261

Change TypeCriteria additions and revisions (material)

Effective DateMar 1, 2026

Next Review Date

Key ActionPrior authorization must be obtained for cladribine; approvals are issued for the durations specified (initial and reauthorization: 1 year).

SourceLink

On This Page

b) One specified high-efficacy agent: According to the prescriber, the patient has experienced inadequate efficacy or significant intolerance to one of Kesimpta (ofatumumab subcutaneous injection), a natalizumab intravenous product (Tysabri, biosimilar), Briumvi (ublituximabxiiy intravenous infusion), Lemtrada (alemtuzumab intravenous infusion), Ocrevus (ocrelizumab intravenous infusion), or Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq subcutaneous injection)

c) Prior cladribine: Patient has received cladribine in the past

d) Highly-active or aggressive multiple sclerosis (ONE of)

Patient has demonstrated rapidly advancing deterioration(s) in physical functioning
Examples include loss of mobility or lower levels of ambulation and severe changes in strength or coordination
Disabling relapse(s) with suboptimal response to systemic corticosteroids
MRI findings suggest highly active or aggressive multiple sclerosis
Examples include new, enlarging, or a high burden of T2 lesions or gadolinium-enhancing lesions
Manifestations of multiple sclerosis-related cognitive impairment

Medication is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis

B) Patient is Currently Receiving Cladribine for ≥ 1 Year (Reauthorization)

Patient has a relapsing form of multiple sclerosis
Examples include relapsing remitting disease and active secondary progressive disease
ONE of
- a) Beneficial objective response: Patient experienced a beneficial clinical response when assessed by at least one objective measure
  Examples include stabilization or reduced worsening on MRI (absence or decrease in gadolinium enhancing lesions or new/enlarging T2 lesions); stabilization or reduced worsening on EDSS; achievement of NEDA-3 or NEDA-4; improvement on FSIQ-RMS; reduction or absence of relapses; improvement or maintenance on six-minute walk test or 12-Item MS Walking Scale; improvement on MSFC; attenuation of brain volume loss
- b) Symptomatic stabilization or improvement: Patient experienced stabilization, slowed progression, or improvement in at least one symptom such as motor function, fatigue, vision, bowel/bladder function, spasticity, walking/gait, or pain/numbness/tingling sensation
Medication is prescribed by or in consultation with a neurologist or a physician who specializes in the treatment of multiple sclerosis

General Policy Statement / Prior Authorization

Prior Authorization is required for benefit coverage of cladribine. All approvals are provided for the duration cited below.

ALL of the following

Cladribine must be prescribed by or in consultation with a physician who specializes in the condition being treated
Requires specialist involvement due to evaluation, diagnosis, monitoring needs
Approvals are provided for the duration noted in the FDA-Approved Indication sections (initial: 1 year; reauthorization: 1 year)

Conditions Not Covered (Not Medically Necessary)

Cladribine for any other use is considered not medically necessary including the following:

ALL of the following

Clinically isolated syndrome
Cladribine is not recommended for use in patients with clinically isolated syndrome due to its safety profile.
Current use in combination with other disease-modifying agents used for multiple sclerosis
These agents are not indicated for use in combination; additional data are required
Non-relapsing forms of multiple sclerosis
The efficacy of cladribine has not been established in patients with multiple sclerosis with non-relapsing forms of the disease. Example: primary progressive multiple sclerosis.

Documentation Required

Document prior DMT failures or intolerance

For initial therapy, document inadequate efficacy or significant intolerance to the required prior disease-modifying therapies per the selected initial criterion — either inadequate efficacy/intolerance to two DMTs OR to one specified high‑efficacy agent — or documentation of highly‑active/aggressive disease features. See the Appendix for qualifying agents and examples; qualifying high‑efficacy agents include Kesimpta, a natalizumab intravenous product (Tysabri, biosimilar), Briumvi, Lemtrada, Ocrevus, and Ocrevus Zunovo.

Denial Risk

Not medically necessary exclusions

Claims for cladribine for clinically isolated syndrome, non‑relapsing MS (e.g., primary progressive MS), or concomitant use with other disease‑modifying MS agents will be considered not medically necessary and denied.

08/15/2024change

Added requirement that cladribine must be prescribed by or in consultation with a neurologist or a physician who specializes in multiple sclerosis (specialist prescribing requirement) (material).

08/15/2024change

Removed preferred product requirements for Employer and IFP (operational/formulary preference removal).

12/01/2024change

Added a definition for documentation (non-material selected revision).

03/01/2026changeLatest

Policy name changed to add 'Oral - Other' and generic Mavenclad was added to the policy with related criterion and appendix updates (including noting Mavenclad availability as a generic and appendix entries for Tysabri/biosimilar); Ocrevus Zunovo was also noted as added to the appendix (material).